Skip to main content
Log in

Trastuzumab Monotherapy

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Baselga J, Tripathy D, Mendelsohn et al.: Phase II study of weekly, intravenous, recombinant, humanized anti-p185 Her-2 monoclonal antibody in patients with Her 2/neu overexpressing metastatic breast cancer. J Clin Oncol 14: 737–744, 1996

    Google Scholar 

  2. Cobleigh MA, Vogel CL, Tripathy D et al.: Multinational study of the efficacy and safety of humanized anti-Her-2 monoclonal antibody in women who have Her-2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17: 2639–2648, 1999

    Google Scholar 

  3. Vogel CL, Cobleigh MA, Tripathy D et al.: Efficacy and safety of trastuzumab as a single agent in first line treatment of Her-2 overexpressing metastatic breast cancer. J Clin Oncol 120: 719–726, 2002

    Google Scholar 

  4. Carbonell-Castellon X, Casteneda-Soto NJ, Clemens M et al.: Efficacy and safety of 3 weekly Herceptin monotherapy in women with Her-2 positive metastatic breast cancer: preliminary report from a phase II study. Proc Am Soc Clin Oncol 21: 19a, 2002 (abstract 73)

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vogel, C. Trastuzumab Monotherapy. Breast Cancer Res Treat 81 (Suppl 1), 67–68 (2003). https://doi.org/10.1023/A:1026325008419

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1026325008419

Keywords

Navigation